Epilepsy drugs: Key market research findings
- Arrival of new-generation anti-epileptic drugs
- Increased adoption of reformulation strategies by vendors
Technavio has added a new market research report on the European epilepsy drugs market, to its epilepsy portfolio. The epilepsy drugs market in Europe is expected to grow at a CAGR of around 3% between 2015 and 2019, owing to the increased adoption of reformulation strategies by market vendors. Germany is the highest revenue contributor to the Europe epilepsy drugs market, generating more than US $320 million over the next four years. Increased penetration of approved drugs is propelling growth of the German epileptic drugs market.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for growth, as well as the segments with the maximum growth potential.
“The advent of anti-epileptic drugs in the market is gaining wide acceptance in various European territories, thanks to their superior pharmacokinetic profile when compared to conventional drugs. These third-generation drugs have little or no side effects. Lacosamide, lamotrigine, zonisamide, levetiracetam, and rufinamide are some next-generation drugs gaining popularity in the market,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research.
Manufacturers are increasingly adopting reformulation strategies for rapid action of the marketed drugs with improved features. They are improving the drug delivery systems by offering dispersible and film-coated tablets and increasing the bioavailability of drugs for better medicinal effect. For instance, UCB developed film-coated tablets of Keppra with specific properties such as taste masking, moisture and light protection, superior product appearance, and mechanical resistance.
The leading vendors dominating the Europen epilepsy drugs market are Eisai, UCB Pharma, Pfizer, and GlaxoSmithKline. The recent increase in patient population and the expected launch of promising pipeline drugs during the forecast period are expected to spur the revenues generated by the companies.
A more detailed analysis is available in the Technavio report, Epilepsy Drugs Market in Europe – Market Analysis 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
- Global Epilepsy Market 2014-2018
- Epilepsy Market in the US 2015-2019
- Epilepsy Therapeutics Market in the APAC Region 2015-2019
Further Reading:
